CTLA-4 agonists have the ability to lower CTLA-4 binding to B7 and weaken the B7-1 and B7-2/CTLA-4 suppression systems that allows T cells to perform their anti-tumor functions more effectively. The gene discussed is CTLA4; the disease is neoplasm.